Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy of brentuximab vedotin + AVD combination
(doxorubicine, vinblastine, dacarbazine) in patients with Hodgkin lymphoma stage I / II with
an unfavorable diagnosis, assessed by the negativity of PET (positron emission tomography )
after two cycles of chemotherapy.